sashkin-shutterstock-com-arrows-
Sashkin / Shutterstock.com
8 November 2016PharmaRichard Roberts

Arrow declarations: striking at the heart of commercial uncertainty

Third-party patents present a significant threat to parties seeking to enter the pharmaceuticals market. Often, such challenges may be addressed by undertaking searches to identify specific threats and, where such threats exist, taking action to design around the patent(s); seeking confirmation from the patentee (or a court) that the product or process in question does not infringe; or, if necessary, clearing the way by initiating opposition and/or revocation proceedings against patents of questionable validity.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
12 November 2026   Handing the pharma giant a major win in its feud with Pfizer and BioNTech, the UPC’s injunction reaches well beyond the court’s member states. But with an appeal still possible and parallel disputes playing out across the US and Europe, the fight is far from over.
Pharma
12 November 2026   From GLP-1 drugs to cancer treatments, counterfeiters are exploiting supply chain weaknesses and AI to evade detection. The US chamber’s director of IP tells LSIPR why the fight against fakes is becoming more complex and what lies ahead.
Pharma
10 November 2026   The pharma giant has filed a trademark and passing off claim in London to try and prevent UK consumers from accessing fake weight-loss drugs and other prescription medicines, after its rival’s success in a similar claim earlier in 2026.